Novo Nordisk A/S (NVO) has slashed prices for its blockbuster weight-loss drug Wegovy as competition in the obesity drug market heats up, with ...

Makers of the popular obesity treatments Wegovy and Zepbound are cutting prices for people without insurance. Danish ...

Indianapolis-based Eli Lilly and Co. launched LillyDirect a little more than a year ago and has been ramping up efforts to ...

Drugmaker AbbVie has agreed to license a weight-loss drug currently in development from Gubra for up to about $2.2 billion, marking its entry into the obesity treatment market.

Novo Nordisk will start selling its obesity drug Wegovy directly to patients at a reduced price, following a similar move ...

Eli Lilly has launched new 7.5 mg and 10 mg single-dose vials of Zepbound (tirzepatide), priced at $499 per month under the ...

HHS Secretary Robert F. Kennedy Jr. is proposing to strip public participation from much of the business his agency conducts ...

As a federal court in Texas hears a case pitting the FDA versus compounders who want to continue to manufacture cheaper ...

A federal judge has effectively ended the ability of compounding pharmacies to make their own copies of Eli Lilly’s weight ...

Pfizer reacts to Donald Trump’s tariff threats on big pharma, another regulatory meeting is canceled under RFK Jr., AbbVie ...

Pfizer on Thursday named James List as the head of the drugmaker's Internal Medicine portfolio, where he will oversee the ...